OBIO’s report, Realizing the Promise of Health Care Innovation: Increasing Value for the Patient, Health System and Economy, was published in 2013 and is a product of the Ontario Bioscience Economic Strategy Team (OBEST®), an initiative launched by OBIO to address the challenges faced by Ontario’s human health technology and bioscience industry.
Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB™) business internship program. This report describes how H2BB™ addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
They always say time changes things, but you actually have to change them yourself.
Andy Warhol
2015 has been a year of growth and opportunity for OBIO with expanding networks and new partnerships. Since we released our five year strategic review in January 2015, there have been significant developments both within our walls and across the ecosystem.
“The best way to predict the future is to create it”
Peter Drucker
Since its founding in 2009, the Ontario Bioscience Innovation Organization (OBIO®) has been engaged in creating the future of Ontario’s biomedical sector through industry-led strategy, policy development, advocacy and high impact programming. OBIO pursues innovative thought leadership within a culture of trust, reaching out to ever growing circles of thinkers and stakeholders.
On May 22, 2015, Member of Parliament for Don Valley West John Carmichael, along with Member of Parliament for Etobicoke-Lakeshore Bernard Trottier announced an investment of up to $3.894 million to support the Ontario Bioscience Innovation Organization’s (OBIO®) efforts to boost investment opportunities for Ontario companies and strengthen innovation for Ontario’s
commercial bioscience cluster.
Over the past several months, OBESTTM has engaged >200 senior representatives from major stakeholder groups across Ontario’s life-sciences sector. The 6-month strategic planning process has resulted in defined priorities and a plan for robust growth and commercial viability of the province’s bioscience industry.
